Oxygenta Pharmaceutical Ltd
OXYGENTAPHLTDNSE
₹0.00▲ +0.00 (+0.00%)
Whole company worth₹194 Cr
1-year range₹43 – ₹75
Not currently trading — we have seen no trades on NSE or BSE recently. It may be suspended, delisted, or renamed after a corporate action. Not a live price.
The short version
A steadily growing, loss-making business.
What Oxygenta Pharmaceutical does
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
Worked out from Oxygenta Pharmaceutical's own filed results and exchange data, in plain words. Where a finance term matters, we say what it means.
01What does it do?
Oxygenta Pharmaceutical is a micro-sized company in pharmaceuticals.
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
- Whole company is worth
- ₹194 crore
- Run by
- Prasad Reddy Battinapatla
- Employees
- 175
- Shareholders
- 10,196 people
- Listed since
- 1997
A very small company by stock-market value — prices can swing hard and trading can be thin.
02Is it growing?
Sales have grown 17% a year for 5 years.
At that pace a business doubles in size roughly every 4 years.
Point at a bar for exact figures · amounts in ₹ crore
03Does it make money?
For every ₹100 it sells, it spends ₹116.
Here is where the money from Oxygenta Pharmaceutical's sales went in FY26, the latest full year it has reported.
₹109
₹100 of sales ends here
- ₹109Costs of running the businessstaff, rent, marketing, power and everything else
- ₹4.4Interest on its loansthe cost of borrowed money
- ₹1.8Wear and tearmachines, stores and buildings losing value over time
- ₹16Lossspent beyond what came in — covered by savings or new money
On the money its owners have put in
It earns ₹41 a year on every ₹100 its owners have invested.
Bank FD ~₹6–7
₹41
₹0₹10₹20₹30₹40₹50
That figure is called return on equity (ROE). Above ₹20 is rare and usually means the business has something competitors struggle to copy. For comparison, a bank fixed deposit pays roughly ₹6–7.
05Who owns it?
Its founders and parent group own 57 of every 100 shares — they control the company.
If the company were split into 100 equal shares, this is who would hold them. 10,196 people and institutions hold its shares.
As filed for the quarter ending 30 Jun 2026. Arrows show the change since the quarter before, in percentage points.
06What is going well, and what to watch
Three things going well, one thing worth watching.
Picked out of the numbers above by fixed rules — the same rules for every company — so nothing here is somebody's opinion.
Going well
- Sales have compounded at 17% a year.
- Earns ₹41 a year on every ₹100 of shareholders' money.
- Has almost no debt — it is not at the mercy of lenders.
Worth watching
- Lost ₹18 crore in its last financial year.
07What happened lately?
Its latest quarter.
Apr–Jun 2026 is the most recent quarter it has reported. Each figure is compared with the same three months a year earlier, because many businesses sell more in some seasons than others.
Sales
₹37 Cr
Loss
₹2.1 Cr
No notable developments in the last few weeks.
Advanced view
Every number, every table, the full chart.
Ten years of statements, quarterly results, peers side by side, technical indicators, analyst estimates, bulk deals and filings.
Ask DoXy
Still have a question about Oxygenta Pharmaceutical?
This page describes Oxygenta Pharmaceutical using its reported figures and exchange data. It is for information only and is not investment advice or a recommendation to buy, sell or hold. DocStoX is not a SEBI-registered investment adviser or research analyst.
Oxygenta Pharmaceutical Ltd (OXYGENTAPHLTD): company summary
Oxygenta Pharmaceutical Ltd (OXYGENTAPHLTD) is a micro-cap Healthcare company valued at ₹194 crore operating in Pharmaceuticals on the NSE and BSE.
Oxygenta Pharmaceutical Ltd (OXYGENTAPHLTD) is a micro-cap Healthcare company valued at ₹194 crore operating in Pharmaceuticals on the NSE and BSE.
- Financial performance
- Revenue has been growing strongly at 54.0% a year over three years. Return on equity is 41.2%.
- Valuation multiples
- A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at -4.66 times book value.
Generated from DocStoX data. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
More Healthcare stocks · Pharmaceuticals
Explore Oxygenta Pharmaceutical Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Oxygenta Pharmaceutical Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedZydus Lifesciences LimitedApollo Hospitals Enterprise LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedMankind Pharma LimitedAurobindo Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Oxygenta Pharmaceutical Ltd with peers
Oxygenta Pharmaceutical Ltd vs Sun Pharmaceutical Industries LimitedOxygenta Pharmaceutical Ltd vs Divi's Laboratories LimitedOxygenta Pharmaceutical Ltd vs Torrent Pharmaceuticals LimitedOxygenta Pharmaceutical Ltd vs Zydus Lifesciences LimitedOxygenta Pharmaceutical Ltd vs Apollo Hospitals Enterprise LimitedOxygenta Pharmaceutical Ltd vs Laurus Labs Limited
Related tools & concepts
Value Oxygenta Pharmaceutical Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing